New Partnership Between myTomorrows and the ALS Association Aims to Expand Clinical Trial Participation

The global health technology company myTomorrows has announced a new partnership with the ALS Association, a US nonprofit organization working to combat amyotrophic lateral sclerosis (ALS) through research, governmental partnerships, and coordinating care and assistance for people with ALS. This partnership will grant the ALS Association access to the myTomorrows.com platform, which connects patients, physicians, researchers, and pharmaceutical companies to facilitate clinical trial recruitment and increase accessibility for research studies.

In this new partnership, the ALS Association will leverage myTomorrows’ extensive database of ongoing trials and patient navigation services so that the nonprofit organization can provide up-to-date information on treatment options and guide individuals towards relevant clinical trials. According to a statement from myTomorrows, the aim of this partnership is to simplify the clinical trial search process for the over 20,000 individuals living with ALS in the United States, enabling them to access and participate in research studies more easily. The partnership will also benefit pharmaceutical companies, which often face challenges in recruiting and enrolling participants in clinical trials, which can delay the process of treatment development.

"We look forward to witnessing the impact of our partnership with the ALS Association, one of the most effective and impactful patient advocacy groups in the United States," said Michel van Harten, CEO of myTomorrows. "ALS is a devastating neuromuscular disease with high unmet needs. Partnering with leading patient advocacy groups such as the ALS Association will help an even larger cohort of ALS patients and their treating physicians discover clinical trials, thereby reducing the barriers they may face in accessing their treatment options."